Key points are not available for this paper at this time.
Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, NCT02792218 and NCT02792231.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Stephen L. Hauser
Amit Bar‐Or
Jeffrey Cohen
New England Journal of Medicine
University of California, San Francisco
Washington University in St. Louis
Cleveland Clinic
Building similarity graph...
Analyzing shared references across papers
Loading...
Hauser et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69936de9a2b7d1228c01f1ec — DOI: https://doi.org/10.1056/nejmoa1917246